11119 North Torrey Pines Road
147 articles with Viking Therapeutics
Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize? For the last few years, investors have been talking up the huge potential of drugs to treat nonalcoholic steatohepatitis, also known as NASH.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders
Viking Therapeutics, Inc. today announced the pricing of its public offering of 9,500,000 shares of its common stock at a price to the public of $18.50 per share.
Viking Therapeutics, Inc. today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
San Diego-based Viking Therapeutics announced positive top-line data from a 12-week Phase II clinical trial of VK2809 in non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C).
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol
Study Achieves Primary Endpoint, Demonstrating Statistically Significant Reductions in LDL-C in Patients Receiving VK2809
The company will participate in three upcoming investor conferences.
Conference call scheduled for 4:30 p.m. ET today
Conference Call Scheduled for Thursday, August 9 at 4:30 p.m. Eastern Time
Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting
Presentation to Highlight Data for Novel, Orally Available SARM in Patients Recovering from Hip Fracture Surgery
Viking Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 8,625,000 shares of its common stock
Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $67.5 million.
Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors
Orchard Therapeutics today announced the appointments of Marc Dunoyer and Charlie Rowland to its board of directors as independent directors.
Viking Therapeutics, Inc. announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
Viking Therapeutics Completes Enrollment in Phase 2 Study of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Top-Line Results Expected in Second Half of 2018
Viking Therapeutics, Inc. announced that the company will release financial results for the first quarter of 2018 after the market close on Wednesday, May 9, 2018.
Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
Viking Therapeutics Inc. announced its financial results for the fourth quarter and year ended December 31, 2017, and provided an update on its clinical pipeline and other corporate developments.
The gross proceeds to Viking from this offering are approximately $63.3M, before deducting underwriting discounts and commissions and other estimated offering expenses.
In addition, Viking has granted the underwriters a 30-day option to purchase up to 1,650,000 additional shares of its common stock.
Viking today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.